Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tecemotide and Bevacizumab in Unresectable Stage III Non-Squamous NSCLC
NCT00828009Phase 2Completed
- Sponsor
- ECOG-ACRIN Cancer Research Group
- Start
- Jan 2011
- Primary completion
- Aug 2018
- Modality
- Peptides, Monoclonal Antibodies, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of tecemotide, bevacizumab in Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC), sponsored by ECOG-ACRIN Cancer Research Group. Started Jan 2011; status: completed.
02
Drugs
tecemotidebevacizumab
03
Conditions
Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC)
Beyond the preview
Go deeper on NCT00828009.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00828009.